Fatigue is a complex phenomenon and an important health concern for many people with chronic inflammatory rheumatic diseases, such as rheumatoid arthritis, psoriatic arthritis, primary Sjögren syndrome and systemic lupus erythematosus. Although some clinical trials have shown the benefits of cognitive behavioural therapy in fatigue management, the effect of this approach is relatively modest, and no curative treatment has been identified. The pathogenesis of fatigue remains unclear. Despite many challenges and limitations, a growing body of research points to roles for the immune system, the central and autonomic nervous systems and the neuroendocrine system in the induction and maintenance of fatigue in chronic diseases. New insights indicate that sleep, genetic susceptibility, metabolic disturbances and other biological and physiological mechanisms contribute to fatigue. Furthermore, understanding of the relationships between psychosocial factors and fatigue is increasing. However, the interrelationships between these diverse mechanisms and fatigue remain poorly defined. In this Review, we outline various biological, physiological and psychosocial determinants of fatigue in inflammatory rheumatic diseases, and propose mechanistic and conceptual models of fatigue to summarize current understanding, stimulate debate and develop further research ideas.
Fatigue is a common and disabling symptom of inflammatory rheumatic diseases.
The mechanisms of fatigue in inflammatory rheumatic diseases are not fully understood but are likely to involve multiple biological, physiological, psychosocial and behavioural mechanisms.
The mechanisms of fatigue in inflammatory rheumatic diseases might change over time and vary between individuals.
Fatigue might reflect the body’s resource management strategy in response to chronic stressors, favouring rationing and storage over expenditure.
Studying fatigue has many challenges; consensus on a study framework for fatigue research and a multidisciplinary approach are essential.
Optimal management of fatigue requires a personalized and holistic approach.
Your institute does not have access to this article
Open Access articles citing this article.
Prevalence and factors associated with fatigue in patients with ulcerative colitis in China: a cross-sectional study
BMC Gastroenterology Open Access 03 June 2022
Pain and Fatigue Improvements in Patients Treated with Repository Corticotropin Injection Across Five Indications: A Narrative Review
Advances in Therapy Open Access 30 May 2022
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Dures, E. et al. Patients’ perspectives on the psychological impact of inflammatory arthritis and meeting the associated support needs: open-ended responses in a multi-centre survey. Musculoskeletal Care 15, 175–185 (2017).
Overman, C. L., Kool, M. B., Da Silva, J. A. P. & Geenen, R. The prevalence of severe fatigue in rheumatic diseases: an international study. Clin. Rheumatol. 35, 409–415 (2016).
Dures, E. et al. “They didn’t tell us, they made us work it out ourselves”: patient perspectives of a cognitive-behavioral program for rheumatoid arthritis fatigue. Arthritis Care Res. 64, 494–501 (2012).
Dures, E. et al. Patient preferences for psychological support in inflammatory arthritis: a multicentre survey. Ann. Rheum. Dis. 75, 142–147 (2016).
Swain, M. G. Fatigue in chronic disease. Clin. Sci. 99, 1–8 (2000).
Druce, K. L. & Basu, N. Predictors of fatigue in rheumatoid arthritis. Rheumatology 58 (Suppl. 5), v29–v34 (2019).
Meijer, J. M. et al. Health-related quality of life, employment and disability in patients with Sjögren’s syndrome. Rheumatology 48, 1077–1082 (2009).
Westhoff, G., Dörner, T. & Zink, A. Fatigue and depression predict physician visits and work disability in women with primary Sjögren’s syndrome: results from a cohort study. Rheumatology 51, 262–269 (2012).
McCormick, N., Marra, C. A., Sadatsafavi, M., Kopec, J. A. & Aviña-Zubieta, J. A. Excess productivity costs of systemic lupus erythematosus, systemic sclerosis, and Sjögren’s Syndrome: a general population-based study. Arthritis Care Res. 71, 142–154 (2019).
Basu, N. et al. Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis. Rheumatology 53, 953–956 (2014).
Borrell-Carrió, F., Suchman, A. L. & Epstein, R. M. The biopsychosocial model 25 years later: principles, practice, and scientific inquiry. Ann. Fam. Med. 2, 576–582 (2004).
Ng, W.-F. & Bowman, S. J. Primary Sjögren’s syndrome: too dry and too tired. Rheumatology 49, 844–853 (2010).
Ahn, G. E. & Ramsey-Goldman, R. Fatigue in systemic lupus erythematosus. Int. J. Clin. Rheumatol. 7, 217–227 (2012).
Pope, J. E. Management of fatigue in rheumatoid arthritis. RMD Open 6, e001084 (2020).
Korte, S. M. & Straub, R. H. Fatigue in inflammatory rheumatic disorders: pathophysiological mechanisms. Rheumatology 58 (Suppl. 5), v35–v50 (2019).
Hackett, K. L. et al. Impaired functional status in primary Sjogren’s syndrome. Arthritis Care Res. 64, 1760–1764 (2012).
Hewlett, S. et al. Patients’ perceptions of fatigue in rheumatoid arthritis: overwhelming, uncontrollable, ignored. Arthritis Rheum. 53, 697–702 (2005).
Primdahl, J. et al. The experience of people with rheumatoid arthritis living with fatigue: a qualitative metasynthesis. BMJ Open 9, e024338 (2019).
Jones, D. E. J., Gray, J. C. & Newton, J. Perceived fatigue is comparable between different disease groups. QJM 102, 617–624 (2009).
Jaime-Lara, R. B., Koons, B. C., Matura, L. A., Hodgson, N. A. & Riegel, B. A qualitative metasynthesis of the experience of fatigue across five chronic conditions. J. Pain. Symptom. Manag. 59, 1320–1343 (2020).
Norheim, K. B., Jonsson, G. & Omdal, R. Biological mechanisms of chronic fatigue. Rheumatology 50, 1009–1018 (2011).
Bower, J. E. Cancer-related fatigue — mechanisms, risk factors, and treatments. Nat. Rev. Clin. Oncol. 11, 597–609 (2014).
Jhamb, M., Weisbord, S. D., Steel, J. L. & Unruh, M. Fatigue in patients receiving maintenance dialysis: a review of definitions, measures, and contributing factors. Am. J. Kidney Dis. 52, 353–365 (2008).
James, K. et al. A transcriptional signature of fatigue derived from patients with primary Sjögren’s syndrome. PLoS ONE 10, e0143970 (2015).
Da Costa, D. et al. Dimensions of fatigue in systemic lupus erythematosus: relationship to disease status and behavioral and psychosocial factors. J. Rheumatol. 33, 1282–1288 (2006).
Bruce, I. N., Mak, V. C., Hallett, D. C., Gladman, D. D. & Urowitz, M. B. Factors associated with fatigue in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 58, 379–381 (1999).
Tench, C., McCurdie, I., White, P. & d’Cruz, D. The prevalence and associations of fatigue in systemic lupus erythematosus. Rheumatology 39, 1249–1254 (2000).
Azizoddin, D. R. et al. Fatigue in systemic lupus: the role of disease activity and its correlates. Lupus 28, 163–173 (2019).
Hewlett, S., Dures, E. & Almeida, C. Measures of fatigue: Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire (BRAF MDQ), Bristol Rheumatoid Arthritis Fatigue Numerical Rating Scales (BRAF NRS) for severity, effect, and coping, Chalder Fatigue Questionnaire (CFQ), Checklist Individual Strength (CIS20R and CIS8R), Fatigue Severity Scale (FSS), Functional Assessment Chronic Illness Therapy (Fatigue) (FACIT-F), Multi-Dimensional Assessment of Fatigue (MAF), Multi-Dimensional Fatigue Inventory (MFI), Pediatric Quality Of Life (PedsQL) Multi-Dimensional Fatigue Scale, Profile of Fatigue (ProF), Short Form 36 Vitality Subscale (SF-36 VT), and Visual Analog Scales (VAS). Arthritis Care Res. 63 (Suppl. 11), S263–S286 (2011).
Santos, E. J. F., Duarte, C., da Silva, J. A. P. & Ferreira, R. J. O. The impact of fatigue in rheumatoid arthritis and the challenges of its assessment. Rheumatology 58 (Suppl. 5), v3–v9 (2019).
Geenen, R. & Dures, E. A biopsychosocial network model of fatigue in rheumatoid arthritis: a systematic review. Rheumatology 58 (Suppl. 5), v10–v21 (2019).
Dantzer, R., O’Connor, J. C., Freund, G. G., Johnson, R. W. & Kelley, K. W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9, 46–56 (2008).
Lopes, P. C., Block, P. & König, B. Infection-induced behavioural changes reduce connectivity and the potential for disease spread in wild mice contact networks. Sci. Rep. 6, 31790 (2016).
Muskardin, T. L. W. & Niewold, T. B. Type I interferon in rheumatic diseases. Nat. Rev. Rheumatol. 14, 214–228 (2018).
Howard Tripp, N. et al. Fatigue in primary Sjögren’s syndrome is associated with lower levels of proinflammatory cytokines. RMD Open 2, e000282 (2016).
Umare, V. et al. Effect of proinflammatory cytokines (IL-6, TNF-α, and IL-1β) on clinical manifestations in Indian SLE patients. Mediators Inflamm. 2014, 385297 (2014).
Druce, K. L., Bhattacharya, Y., Jones, G. T., Macfarlane, G. J. & Basu, N. Most patients who reach disease remission following anti-TNF therapy continue to report fatigue: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology 55, 1786–1790 (2016).
Tarn, J. R. et al. Symptom-based stratification of patients with primary Sjögren’s syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. Lancet Rheumatol. 1, e85–e94 (2019).
Lendrem, D. et al. Do the EULAR Sjögren’s syndrome outcome measures correlate with health status in primary Sjögren’s syndrome? Rheumatology 54, 655–659 (2015).
Devauchelle-Pensec, V. et al. Improvement of Sjögren’s syndrome after two infusions of rituximab (anti-CD20). Arthritis Care Res. 57, 310–317 (2007).
Dass, S. et al. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann. Rheum. Dis. 67, 1541–1544 (2008).
Carubbi, F. et al. Efficacy and safety of rituximab treatment in early primary Sjögren’s syndrome: a prospective, multi-center, follow-up study. Arthritis Res. Ther. 15, R172 (2013).
St Clair, E. W. et al. Rituximab therapy for primary Sjögren’s Syndrome: an open-label clinical trial and mechanistic analysis. Arthritis Rheum. 65, 1097–1106 (2013).
Devauchelle-Pensec, V. et al. Treatment of primary Sjögren syndrome with rituximab: a randomized trial. Ann. Intern. Med. 160, 233–242 (2014).
Bowman, S. J. et al. Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjögren’s Syndrome. Arthritis Rheumatol. 69, 1440–1450 (2017).
Posada, J. et al. Improvement of severe fatigue following nuclease therapy in patients with primary Sjögren’s syndrome: a randomized clinical trial. Arthritis Rheumatol. 73, 143–150 (2021).
Davies, K. et al. Fatigue in primary Sjögren’s syndrome (pSS) is associated with lower levels of proinflammatory cytokines: a validation study. Rheumatol. Int. 39, 1867–1873 (2019).
Almeida, C. et al. Biologic interventions for fatigue in rheumatoid arthritis. Cochrane Database Syst. Rev. 2016, CD008334 (2016).
Pollard, L. C., Choy, E. H., Gonzalez, J., Khoshaba, B. & Scott, D. L. Fatigue in rheumatoid arthritis reflects pain, not disease activity. Rheumatology 45, 885–889 (2006).
Navarra, S. V. et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377, 721–731 (2011).
Furie, R. et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 63, 3918–3930 (2011).
Bangert, E., Wakani, L., Merchant, M., Strand, V. & Touma, Z. Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: review of clinical studies. Patient Relat. Outcome Meas. 10, 1–7 (2019).
Strand, V. et al. Long-term impact of belimumab on health-related quality of life and fatigue in patients with systemic lupus erythematosus: six years of treatment. Arthritis Care Res. 71, 829–838 (2019).
Russell, A. et al. Persistent fatigue induced by interferon-alpha: a novel, inflammation-based, proxy model of chronic fatigue syndrome. Psychoneuroendocrinology 100, 276–285 (2019).
Sharpe, M. & Wilks, D. Fatigue. BMJ 325, 480 (2002).
Taylor, J. L., Amann, M., Duchateau, J., Meeusen, R. & Rice, C. L. Neural contributions to muscle fatigue: from the brain to the muscle and back again. Med. Sci. Sports Exerc. 48, 2294–2306 (2016).
Quan, N. & Banks, W. A. Brain-immune communication pathways. Brain Behav. Immun. 21, 727–735 (2007).
Stetler, R. A. et al. Heat shock proteins: cellular and molecular mechanisms in the central nervous system. Prog. Neurobiol. 92, 184–211 (2010).
Elenkov, I. J., Kovács, K., Duda, E., Stark, E. & Vizi, E. Z. Presynaptic inhibitory effect of TNF-alpha on the release of noradrenaline in isolated median eminence. Neuroimmunology 41, 117–120 (1992).
Yamashita, M. & Yamamoto, T. Tryptophan circuit in fatigue: from blood to brain and cognition. Brain Res. 1675, 116–126 (2017).
Åkesson, K. et al. Kynurenine pathway is altered in patients with SLE and associated with severe fatigue. Lupus Sci. Med. 5, e000254 (2018).
Schröcksnadel, K., Wirleitner, B., Winkler, C. & Fuchs, D. Monitoring tryptophan metabolism in chronic immune activation. Clin. Chim. Acta 364, 82–90 (2006).
Karageorgas, T. et al. Fatigue in primary Sjögren’s syndrome: clinical, laboratory, psychometric, and biologic associations. Arthritis Care Res. 68, 123–131 (2016).
Strasser, B. et al. Effects of exhaustive aerobic exercise on tryptophan-kynurenine metabolism in trained athletes. PLoS ONE 11, e0153617 (2016).
Malhotra, R. et al. Tryptophan and kynurenine levels and its association with sleep, nonphysical fatigue, and depression in chronic hemodialysis patients. J. Ren. Nutr. 27, 260–266 (2017).
Larssen, E. et al. Fatigue in primary Sjögren’s syndrome: a proteomic pilot study of cerebrospinal fluid. SAGE Open Med. 7, 2050312119850390 (2019).
Harboe, E. et al. Fatigue in primary Sjögren’s syndrome — a link to sickness behaviour in animals? Brain Behav. Immun. 23, 1104–1108 (2009).
Bårdsen, K. et al. Interleukin-1-related activity and hypocretin-1 in cerebrospinal fluid contribute to fatigue in primary Sjögren’s syndrome. J. Neuroinflammation 16, 102 (2019).
Schrepf, A. et al. A multi-modal MRI study of the central response to inflammation in rheumatoid arthritis. Nat. Commun. 9, 2243 (2018).
Basu, N. et al. Neural correlates of fatigue in granulomatosis with polyangiitis: a functional magnetic resonance imaging study. Rheumatology 53, 2080–2087 (2014).
Kraynak, T. E., Marsland, A. L., Wager, T. D. & Gianaros, P. J. Functional neuroanatomy of peripheral inflammatory physiology: a meta-analysis of human neuroimaging studies. Neurosci. Biobehav. Rev. 94, 76–92 (2018).
Goñi, M., Basu, N., Murray, A. D. & Waiter, G. D. Neural indicators of fatigue in chronic diseases: a systematic review of MRI studies. Diagnostics 8, 42 (2018).
Kutlubaev, M. A., Duncan, F. H. & Mead, G. E. Biological correlates of post-stroke fatigue: a systematic review. Acta Neurol. Scand. 125, 219–227 (2012).
Mastorakos, G., Chrousos, G. P. & Weber, J. S. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J. Clin. Endocrinol. Metab. 77, 1690–1694 (1993).
Tsigos, C. et al. Dose effects of recombinant human interleukin-6 on pituitary hormone secretion and energy expenditure. Neuroendocrinology 66, 54–62 (1997).
Johnson, E. O., Vlachoyiannopoulos, P. G., Skopouli, F. N., Tzioufas, A. G. & Moutsopoulos, H. M. Hypofunction of the stress axis in Sjögren’s syndrome. J. Rheumatol. 25, 1508–1514 (1998).
Crofford, L. J. et al. Circadian relationships between interleukin (IL)-6 and hypothalamic-pituitary-adrenal axis hormones: failure of IL-6 to cause sustained hypercortisolism in patients with early untreated rheumatoid arthritis. J. Clin. Endocrinol. Metab. 82, 1279–1283 (1997).
Straub, R. H., Paimela, L., Peltomaa, R., Schölmerich, J. & Leirisalo-Repo, M. Inadequately low serum levels of steroid hormones in relation to interleukin-6 and tumor necrosis factor in untreated patients with early rheumatoid arthritis and reactive arthritis. Arthritis Rheum. 46, 654–662 (2002).
Gutiérrez, M. A., Garcia, M. E., Rodriguez, J. A., Rivero, S. & Jacobelli, S. Hypothalamic-pituitary-adrenal axis function and prolactin secretion in systemic lupus erythematosus. Lupus 7, 404–408 (1998).
Evers, A. W. et al. Does stress affect the joints? Daily stressors, stress vulnerability, immune and HPA axis activity, and short-term disease and symptom fluctuations in rheumatoid arthritis. Ann. Rheum. Dis. 73, 1683–1688 (2014).
Jump, R. L. et al. Fatigue in systemic lupus erythematosus: contributions of disease activity, pain, depression, and perceived social support. J. Rheumatol. 32, 1699–1705 (2005).
Cutolo, M., Sulli, A., Pizzorni, C., Craviotto, C. & Straub, R. H. Hypothalamic-pituitary-adrenocortical and gonadal functions in rheumatoid arthritis. Ann. N. Y. Acad. Sci. 992, 107–117 (2003).
Moulton, V. R. Sex hormones in acquired immunity and autoimmune disease. Front. Immunol. 9, 2279 (2018).
Johnson, E. O. & Moutsopoulos, H. M. Neuroendocrine manifestations in Sjögren’s syndrome. Relation to the neurobiology of stress. Ann. N. Y. Acad. Sci. 917, 797–808 (2000).
Sundman, E. & Olofsson, P. S. Neural control of the immune system. Adv. Physiol. Educ. 38, 135–139 (2014).
Porges, S. W. The polyvagal theory: phylogenetic substrates of a social nervous system. Int. J. Psychophysiol. 42, 123–146 (2001).
Brunetta, E. et al. Autonomic abnormalities in patients with primary Sjogren’s syndrome — preliminary results. Front. Physiol. 10, 1104 (2019).
Newton, J. L. et al. Autonomic symptoms are common and are associated with overall symptom burden and disease activity in primary Sjögren’s syndrome. Ann. Rheum. Dis. 71, 1973–1979 (2012).
Koh, J. H. et al. Pain, xerostomia, and younger age are major determinants of fatigue in Korean patients with primary Sjögren’s syndrome: a cohort study. Scand. J. Rheumatol. 46, 49–55 (2017).
Mandl, T., Wollmer, P., Manthorpe, R. & Jacobsson, L. T. Autonomic and orthostatic dysfunction in primary Sjögren’s syndrome. J. Rheumatol. 34, 1869–1874 (2007).
Fox, R. I., Kang, H. I., Ando, D., Abrams, J. & Pisa, E. Cytokine mRNA expression in salivary gland biopsies of Sjögren’s syndrome. J. Immunol. 152, 5532–5539 (1994).
Barendregt, P. J. et al. Parasympathetic failure does not contribute to ocular dryness in primary Sjögren’s syndrome. Ann. Rheum. Dis. 58, 746–750 (1999).
Kovács, L. et al. Cardiovascular autonomic dysfunction in primary Sjögren’s syndrome. Rheumatology 43, 95–99 (2004).
Barendregt, P. J., Tulen, J. H., van den Meiracker, A. H. & Markusse, H. M. Spectral analysis of heart rate and blood pressure variability in primary Sjögren’s syndrome. Ann. Rheum. Dis. 61, 232–236 (2002).
Niemelä, R. K., Hakala, M., Huikuri, H. V. & Airaksinen, K. E. Comprehensive study of autonomic function in a population with primary Sjögren’s syndrome. No evidence of autonomic involvement. J. Rheumatol. 30, 74–79 (2003).
Tumiati, B., Perazzoli, F., Negro, A., Pantaleoni, M. & Regolisti, G. Heart rate variability in patients with Sjögren’s syndrome. Clin. Rheumatol. 19, 477–480 (2000).
Tarn, J., Legg, S., Mitchell, S., Simon, B. & Ng, W. F. The effects of noninvasive vagus nerve stimulation on fatigue and immune responses in patients with primary Sjögren’s syndrome. Neuromodulation 22, 580–585 (2019).
Ingegnoli, F. et al. The link between autonomic nervous system and rheumatoid arthritis: from bench to bedside. Front. Med. 7, 589079 (2020).
Bortoluzzi, A., Silvagni, E., Furini, F., Piga, M. & Govoni, M. Peripheral nervous system involvement in systemic lupus erythematosus: a review of the evidence. Clin. Exp. Rheumatol. 37, 146–155 (2019).
Stojanovich, L. Autonomic dysfunction in autoimmune rheumatic disease. Autoimmun. Rev. 8, 569–572 (2009).
Koopman, F. A. et al. Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis. Proc. Natl Acad. Sci. USA 113, 8284–8289 (2016).
Genovese, M. C. et al. Safety and efficacy of neurostimulation with a miniaturised vagus nerve stimulation device in patients with multidrug-refractory rheumatoid arthritis: a two-stage multicentre, randomised pilot study. Lancet Rheumatol. 2, e527–e538 (2020).
Thomas, K. S., Motivala, S., Olmstead, R. & Irwin, M. R. Sleep depth and fatigue: role of cellular inflammatory activation. Brain Behav. Immun. 25, 53–58 (2011).
Meerlo, P., Sgoifo, A. & Suchecki, D. Restricted and disrupted sleep: effects on autonomic function, neuroendocrine stress systems and stress responsivity. Sleep Med. Rev. 12, 197–210 (2008).
Lewis, I., Hackett, K. L., Ng, W.-F., Ellis, J. & Newton, J. L. A two-phase cohort study of the sleep phenotype within primary Sjögren’s syndrome and its clinical correlates. Clin. Exp. Rheumatol. 37 (Suppl. 118), 78–82 (2019).
Irwin, M. R. Sleep and inflammation: partners in sickness and in health. Nat. Rev. Immunol. 19, 702–715 (2019).
Guyon, A. et al. Adverse effects of two nights of sleep restriction on the hypothalamic-pituitary-adrenal axis in healthy men. J. Clin. Endocrinol. Metab. 99, 2861–2868 (2014).
Grabovac, I. et al. Sleep quality in patients with rheumatoid arthritis and associations with pain, disability, disease duration, and activity. J. Clin. Med. 7, 336 (2018).
Sariyildiz, M. A. et al. Sleep quality in rheumatoid arthritis: relationship between the disease severity, depression, functional status and the quality of life. J. Clin. Med. Res. 6, 44–52 (2014).
Palagini, L. et al. Sleep disorders and systemic lupus erythematosus. Lupus 23, 115–123 (2014).
Hackett, K. L. et al. An investigation into the prevalence of sleep disturbances in primary Sjögren’s syndrome: a systematic review of the literature. Rheumatology 56, 570–580 (2017).
Reinisch, T. & Hinz, H. In Encyclopedic Reference of Genomics and Proteomics in Molecular Medicine (eds Ganten, D. & Ruckpaul, K.) Vol. 9, 919 (Springer, 2006).
Hausladen, A., Privalle, C. T., Keng, T., DeAngelo, J. & Stamler, J. S. Nitrosative stress: activation of the transcription factor OxyR. Cell 86, 719–729 (1996).
Avalos, I. et al. Oxidative stress in systemic lupus erythematosus: relationship to disease activity and symptoms. Lupus 16, 195–200 (2007).
Shah, D., Kiran, R., Wanchu, A. & Bhatnagar, A. Oxidative stress in systemic lupus erythematosus: relationship to Th1 cytokine and disease activity. Immunol. Lett. 129, 7–12 (2010).
Powers, S. K., Ji, L. L., Kavazis, A. N. & Jackson, M. J. Reactive oxygen species: impact on skeletal muscle. Compr. Physiol. 1, 941–969 (2011).
Novelli, G. P., Bracciotti, G. & Falsini, S. Spin-trappers and vitamin E prolong endurance to muscle fatigue in mice. Free Radic. Biol. Med. 8, 9–13 (1990).
Shindoh, C., DiMarco, A., Thomas, A., Manubay, P. & Supinski, G. Effect of N-acetylcysteine on diaphragm fatigue. J. Appl. Physiol. 68, 2107–2113 (1990).
Dassouki, T. et al. Objectively measured physical activity and its influence on physical capacity and clinical parameters in patients with primary Sjögren’s syndrome. Lupus 26, 690–697 (2017).
Miyamoto, S. T. et al. Supervised walking improves cardiorespiratory fitness, exercise tolerance, and fatigue in women with primary Sjogren’s syndrome: a randomized-controlled trial. Rheumatol. Int. 39, 227–238 (2019).
Ng, W. F. et al. Physical activity but not sedentary activity is reduced in primary Sjogren’s syndrome. Rheumatol. Int. 37, 623–631 (2017).
Wouters, E. J. M. et al. Physical activity and physical activity cognitions are potential factors maintaining fatigue in patients with primary Sjögren’s syndrome. Ann. Rheum. Dis. 71, 668–673 (2012).
Keyser, R. E. et al. Evidence for aerobic insufficiency in women with systemic lupus erythematosus. Arthritis Rheum. 49, 16–22 (2003).
Metsios, G. S. et al. Cardiorespiratory fitness levels and their association with cardiovascular profile in patients with rheumatoid arthritis: a cross-sectional study. Rheumatology 54, 2215–2220 (2015).
Løppenthin, K. et al. Physical activity and the association with fatigue and sleep in Danish patients with rheumatoid arthritis. Rheumatol. Int. 35, 1655–1664 (2015).
Rongen-van Dartel, S. A. et al. Effect of aerobic exercise training on fatigue in rheumatoid arthritis: a meta-analysis. Arthritis Care Res. 67, 1054–1062 (2015).
Cramp, F. The role of non-pharmacological interventions in the management of rheumatoid-arthritis-related fatigue. Rheumatology 58 (Suppl. 5), v22–v28 (2019).
Cramp, F. et al. Non-pharmacological interventions for fatigue in rheumatoid arthritis. Cochrane Database Syst. Rev. 8, CD008322 (2013).
Robb-Nicholson, L. C. et al. Effects of aerobic conditioning in lupus fatigue: a pilot study. Rheumatology 28, 500–505 (1989).
Tench, C., McCarthy, J., McCurdie, I., White, P. & D’Cruz, D. Fatigue in systemic lupus erythematosus: a randomized controlled trial of exercise. Rheumatology 42, 1050–1054 (2003).
Andonian, B. J. & Huffman, K. M. Skeletal muscle disease in rheumatoid arthritis: the center of cardiometabolic comorbidities? Curr. Opin. Rheumatol. 32, 297–306 (2020).
An, H. J. et al. Sarcopenia in autoimmune and rheumatic diseases: a comprehensive review. Int. J. Mol. Sci. 21, 5678 (2020).
Lindvall, B., Bengtsson, A., Ernerudh, J. & Eriksson, P. Subclinical myositis is common in primary Sjögren’s syndrome and is not related to muscle pain. J. Rheumatol. 29, 717–725 (2002).
Baker, J. F. et al. Deficits in muscle mass, muscle density, and modified associations with fat in rheumatoid arthritis. Arthritis Care Res. 66, 1612–1618 (2014).
Caimmi, C. et al. Malnutrition and sarcopenia in a large cohort of patients with systemic sclerosis. Clin. Rheumatol. 37, 987–997 (2018).
Tournadre, A., Pereira, B., Gossec, L., Soubrier, M. & Dougados, M. Impact of comorbidities on fatigue in rheumatoid arthritis patients: results from a nurse-led program for comorbidities management (COMEDRA). Joint Bone Spine 86, 55–60 (2019).
Feldthusen, C., Grimby-Ekman, A., Forsblad-d’Elia, H., Jacobsson, L. & Mannerkorpi, K. Explanatory factors and predictors of fatigue in persons with rheumatoid arthritis: a longitudinal study. J. Rehabil. Med. 48, 469–476 (2016).
Katz, P. et al. Role of sleep disturbance, depression, obesity, and physical inactivity in fatigue in rheumatoid arthritis. Arthritis Care Res. 68, 81–90 (2016).
Chaiamnuay, S. et al. The impact of increased body mass index on systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA XLVI) [corrected]. J. Clin. Rheumatol. 13, 128–133 (2007).
Oeser, A., Chung, C. P., Asanuma, Y., Avalos, I. & Stein, C. M. Obesity is an independent contributor to functional capacity and inflammation in systemic lupus erythematosus. Arthritis Rheum. 52, 3651–3659 (2005).
Pajoutan, M., Ghesmaty Sangachin, M. & Cavuoto, L. A. Central and peripheral fatigue development in the shoulder muscle with obesity during an isometric endurance task. BMC Musculoskelet. Disord. 18, 314 (2017).
Osborn, O. & Olefsky, J. M. The cellular and signaling networks linking the immune system and metabolism in disease. Nat. Med. 18, 363–374 (2012).
Matcham, F., Rayner, L., Steer, S. & Hotopf, M. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology 52, 2136–2148 (2013).
Gold, S. M. et al. Comorbid depression in medical diseases. Nat. Rev. Dis. Prim. 6, 69 (2020).
Hackett, K. L. et al. Pain and depression are associated with both physical and mental fatigue independently of comorbidities and medications in primary Sjögren’s syndrome. RMD Open 5, e000885 (2019).
Wilson, N., Lee, J. J. & Bei, B. Postpartum fatigue and depression: a systematic review and meta-analysis. J. Affect. Disord. 246, 224–233 (2019).
World Health Organisation. ICD-10 classification of mental and behavioural disorders (WHO, 2016).
Nerurkar, L., Siebert, S., McInnes, I. B. & Cavanagh, J. Rheumatoid arthritis and depression: an inflammatory perspective. Lancet Psychiatry 6, 164–173 (2019).
Bårdsen, K. et al. Heat shock proteins and chronic fatigue in primary Sjögren’s syndrome. Innate Immun. 22, 162–167 (2016).
Mondelli, V. & Vernon, A. C. From early adversities to immune activation in psychiatric disorders: the role of the sympathetic nervous system. Clin. Exp. Immunol. 197, 319–328 (2019).
Rossi, S. et al. Neuroinflammation drives anxiety and depression in relapsing-remitting multiple sclerosis. Neurology 89, 1338–1347 (2017).
Omdal, R., Mellgren, S. I. & Norheim, K. B. Pain and fatigue in primary Sjögren’s syndrome. Rheumatology https://doi.org/10.1093/rheumatology/kez027 (2019).
Nichilatti, L. P., Fernandes, J. M. & Marques, C. P. Physiopathology of pain in systemic erythematosus lupus. Lupus 29, 721–726 (2020).
Morgan, C., Bland, A. R., Maker, C., Dunnage, J. & Bruce, I. N. Individuals living with lupus: findings from the LUPUS UK Members Survey 2014. Lupus 27, 681–687 (2018).
Sanderson, T., Morris, M., Calnan, M., Richards, P. & Hewlett, S. Patient perspective of measuring treatment efficacy: the rheumatoid arthritis patient priorities for pharmacologic interventions outcomes. Arthritis Care Res. 62, 647–656 (2010).
Bower, J. E. Behavioral symptoms in patients with breast cancer and survivors. J. Clin. Oncol. 26, 768–777 (2008).
Treharne, G. J. et al. Predictors of fatigue over 1 year among people with rheumatoid arthritis. Psychol. Health Med. 13, 494–504 (2008).
Camacho, E. M., Verstappen, S. M., Chipping, J. & Symmons, D. P. Learned helplessness predicts functional disability, pain and fatigue in patients with recent-onset inflammatory polyarthritis. Rheumatology 52, 1233–1238 (2013).
Jacobsen, P. B., Andrykowski, M. A. & Thors, C. L. Relationship of catastrophizing to fatigue among women receiving treatment for breast cancer. J. Consult. Clin. Psychol. 72, 355–361 (2004).
Segal, B. M. et al. Pain in primary Sjögren syndrome: the role of catastrophizing and negative illness perceptions. Scand. J. Rheumatol. 43, 234–241 (2014).
Hewlett, S. et al. Reducing arthritis fatigue impact: two-year randomised controlled trial of cognitive behavioural approaches by rheumatology teams (RAFT). Ann. Rheum. Dis. 78, 465–472 (2019).
Sanada, K. et al. Effects of mindfulness-based interventions on biomarkers and low-grade inflammation in patients with psychiatric disorders: a meta-analytic review. Int. J. Mol. Sci. 21, 2484 (2020).
Nadarajah, M. & Goh, H. T. Post-stroke fatigue: a review on prevalence, correlates, measurement, and management. Top. Stroke Rehabil. 22, 208–220 (2015).
Sterling, P. Allostasis: a model of predictive regulation. Physiol. Behav. 106, 5–15 (2012).
Smets, E. M., Garssen, B., Bonke, B. & De Haes, J. C. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J. Psychom. Res. 39, 315–325 (1995).
Chorus, A. M., Miedema, H. S., Boonen, A. & van der Linden, S. Quality of life and work in patients with rheumatoid arthritis and ankylosing spondylitis of working age. Ann. Rheum. Dis. 62, 1178–1184 (2003).
Barendregt, P. J. et al. Fatigue in primary Sjögren’s syndrome. Ann. Rheum. Dis. 57, 291–295 (1998).
Evers, A. W., Kraaimaat, F. W., Geenen, R., Jacobs, J. W. & Bijlsma, J. W. Stress-vulnerability factors as long-term predictors of disease activity in early rheumatoid arthritis. J. Psychosom. Res. 55, 293–302 (2003).
Zautra, A. J., Fasman, R., Parish, B. P. & Davis, M. C. Daily fatigue in women with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Pain 128, 128–135 (2007).
Drewes, A. M. Pain and sleep disturbances with special reference to fibromyalgia and rheumatoid arthritis. Rheumatology 38, 1035–1038 (1999).
The authors declare no competing interests.
Peer review information
Nature Reviews Rheumatology thanks N. Basu, E. Choy and M. Irwin for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- Recall period
The period over which people are asked to recall a prior event (for example, their fatigue experiences, thoughts and/or behaviours).
- Sickness behaviour
Adaptive behaviours (such as social withdrawal, reduced activity and increased sleep) developed by animals and humans during an acute infection that are presumed to be beneficial for recovery and survival.
Loss of interest in activities that were previously enjoyed and a decreased ability to feel pleasure.
- Neural drive
The activation signals from the central nervous system delivered to the innervating motor neurons of the muscle.
- Hypothalamic–pituitary–adrenal (HPA) axis
Refers to the connections and interactions between the hypothalamus, pituitary gland and adrenal glands.
- Hypothalamic–pituitary–gonadal axis
Refers to the connections and interactions between the hypothalamus, pituitary gland and the gonads.
- Hypothalamic–pituitary–thyroid axis
Refers to the connections and interactions between the hypothalamus, pituitary gland and the thyroid glands.
An umbrella term used to describe conditions attributable to malfunctioning of the autonomic nervous system.
- Sleep disturbances
An umbrella term used to describe the spectrum of sleep disorders, such as difficulty falling asleep, frequent wakening and sleep apnoea.
- Somatic focus
Heightened attention to physical symptoms.
- Learned helplessness
An attributional style whereby a person perceives that they have little control over the events in their life and so responds passively to the challenges that they face.
The ability to be fully aware of one’s thoughts, feelings and sensations without being overly reactive.
- Socratic questioning
The technique of asking focused, probing, open-ended questions that encourage reflection.
About this article
Cite this article
Davies, K., Dures, E. & Ng, WF. Fatigue in inflammatory rheumatic diseases: current knowledge and areas for future research. Nat Rev Rheumatol 17, 651–664 (2021). https://doi.org/10.1038/s41584-021-00692-1
Prevalence and factors associated with fatigue in patients with ulcerative colitis in China: a cross-sectional study
BMC Gastroenterology (2022)
Pain and Fatigue Improvements in Patients Treated with Repository Corticotropin Injection Across Five Indications: A Narrative Review
Advances in Therapy (2022)